Bayer (BAYRY) announced the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena for the treatment of nonatypical endometrial hyperplasia in women.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAYRY:
- Bayer announces MEDRAD Centargo system secures 510(k) clearance
- Dare Bioscience announces return of rights to Oveprene
- Bayer data could ‘somewhat renew’ optimism for Bristol drug, says Morgan Stanley
- Video: Biogen up after Novo weight-loss drug fails to slow Alzheimer’s progress
- Bayer’s Asundexian met primary efficacy, safety endpoints in Phase III study